If you have been reading about fatty acid oxidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-10. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
=== Related compounds === Isometheptene Methylhexanamine (1,3-DMAA) Tuaminoheptane 1,3-Dimethylbutylamine (DMBA) 1,4-Dimethylamylamine (1,4-DMAA) Iproheptine (N-isopropyloctodrine) Heptaminol (hydroxyoctodrine) Oenethyl
== Pathophysiology == Hemoglobin is a protein containing iron that facilitates the transportation of oxygen in red blood cells. Hemoglobin in the blood carries oxygen from the lungs to the other tissues of the body, where it releases the oxygen to enable metabolism. A healthy level of hemoglobin for men is between 13.2 and 16.6 grams per deciliter, and in women between 11.6 and 15 g/dl. Normal adult hemoglobin (HbA) is composed of four protein chains, two α and two β-globin chains arranged into a heterotetramer. In thalassemia, patients have defects in the noncoding region of either the α or β-globin genes, causing ineffective production of normal alpha- or beta-globin chains, which can lead to ineffective erythropoiesis, premature red blood cell destruction, and anemia. The thalassemias are classified according to which chain of the hemoglobin molecule is affected. In α-thalassemias, production of the α-globin chain is affected, while in β-thalassemia, production of the β-globin chain is affected.
=== Legal status === Avutometinib/defactinib was approved for medical use in the United States in May 2025. The FDA granted the application for avutometinib/defactinib priority review, breakthrough therapy, and orphan drug designations.
The Iranian foreign ministry said it was merely reviewing proposals from the US sent through mediators. On 25 March, Pakistani officials delivered a "15-point proposal" from the US to Iran, detailing a ceasefire plan. The US proposal included an end to Iran's nuclear program, limits on its missiles, reopening the Strait of Hormuz, restrictions on Iran's support for armed groups, and sanctions relief for Iran. The Iranians rejected the US proposal, with an anonymous official telling Press TV that "Iran will end the war when it decides to do so and when its own conditions are met". The Iranians issued a "5-point counter-proposal", including an end to US-Israeli attacks on Iran and pro-Iranian forces in Lebanon and Iraq, security guarantees to prevent future Israeli and US aggression, war reparations, and international recognition of Iranian sovereignty over the Strait of Hormuz. On 31 March, Pakistan and China delivered a "5 point initiative" for peace, calling for an immediate end to all hostilities and allowance of humanitarian aid into the region. Trump claimed on 1 April 2026 that Iran had just asked the US for a ceasefire and that the US would consider it once the Strait of Hormuz was "open, free, and clear. Until then, we are blasting Iran into oblivion ... back to the Stone Ages!". Iran's foreign ministry called the claim "false and baseless". The IRGC said the strait "will not be opened to the enemies of this nation through the ridiculous spectacle by the president of the US".
Cells in the body function because of DNA. DNA sits within the nucleus of a cell. Here, parts of DNA are copied and sent to the body of the cell via RNA. The RNA is then used to create proteins, which form the basis for cells, their activity, and their products. Proteins dictate cell function and gene expression, a cell is able to self-regulate by the amount of proteins produced. However, not all cells have DNA; some cells such as mature red blood cells lose their nucleus as they mature.
Sources: en.wikipedia.org
Direct-acting antagonist- which takes up space present on receptors which are otherwise taken up by neurotransmitters themselves. This results in neurotransmitters being blocked from binding to the receptors. An example of one of the most common is called Atropine. Indirect-acting antagonist- drugs that inhibit the release/production of neurotransmitters (e.g., reserpine).
== References == Charpin, Dominique (2010). Writing, Law, and Kingship in Old Babylonian Mesopotamia. University of Chicago Press. ISBN 978-0-226-10159-0. Charpin, Dominique (2023). "Old Babylonian Law and Justice according to Letters and Legal Documents". In Démare-Lafont, Sophie; Fleming, Daniel E. (eds.). Judicial Decisions in the Ancient Near East. SBL Press. pp. 103–222. doi:10.2307/jj.8784672. ISBN 978-1-62837-486-5. Harris, Rivkah (1969). "Notes on the Babylonian Cloister and Hearth: A Review Article". Orientalia. 38 (1): 133–145. ISSN 0030-5367. JSTOR 43079057. Harris, Rivkah (1976). "On Kinship and Inheritance in Old Babylonian Sippar". Iraq. 38 (2): 129–132. doi:10.2307/4200036. ISSN 0021-0889. Jacquet, Antoine (2013). "Family Archives in Mesopotamia during the Old Babylonian Period". In Faraguna, Michele (ed.). Archives and archival documents in ancient societies: Legal Documents in Ancient Societies IV: Trieste 30 September-1 October 2011. Edizioni Università di Trieste. pp. 63–85. ISBN 978-88-8303-460-2. De Graef, Katrien (2016). "Cherchez la femme! The Economic Role of Women in Old Babylonian Sippar". In Lion, Brigitte; Michel, Cécile (eds.). The Role of Women in Work and Society in the Ancient Near East. De Gruyter. pp. 270–295. doi:10.1515/9781614519089-016. ISBN 978-1-61451-908-9.
April 1973: The Movement for the Freedom of Abortion and Contraception (MLAC) is created; it includes feminist and political organizations and announces the practice of then-illegal abortions (Karman method) and group trips abroad for abortion. July 11, 1973: Creation of the Higher Council for Sexual Information, Birth Control, and Family Education. October 8, 1973: Ministerial order extending national agreements concluded in the metallurgy sector; part of it concerns maternity leave compensation. May 1974: Simone Veil becomes Minister of Health; five other women serve as Secretaries of State between 1974 and 1976. July 16, 1974: Creation of the back-to-school allowance. July 23, 1974: The State Secretariat for the Status of Women is created; attached to the Prime Minister, it is assigned to Françoise Giroud. December 4, 1974: Law with various provisions regarding birth control. January 17, 1975: Law of January 17, 1975 on voluntary termination of pregnancy (abortion), also called the "Veil Law," which decriminalizes abortion; adopted for a five-year trial period. Its implementing decree was published on May 13, 1975, providing further details. July 10, 1975: Law amending Article 7 of Ordinance 59-244 of February 4, 1959 (no distinction is made between men and women for the application of this ordinance, except in certain cases where exclusive recruitment of men or women may be planned). July 11, 1975: Law reforming divorce.
===== Juscelino Filho ===== After having strongly criticized the secret budget, a controversial legislative practice initiated during the Jair Bolsonaro government that consists of allocating funds from the public budget to projects defined by parliamentarians with little transparency, Lula appointed Juscelino Filho, affiliated with União Brasil, to the Ministry of Communications. From the end of January onward, a series of allegations fell upon the minister. It was found that Juscelino had used 5 million reais from the Secret Budget for his own benefit, carrying out an asphalt paving project in front of his farm that benefits at least eight people connected to him in Vitorino Freire, a municipality of Maranhão previously governed by his father and currently governed by his sister, where about one-third of the population lives on dirt roads. Another accusation against Juscelino is related to the falsification of information regarding the payment of 385 thousand reais in air taxi services during the 2022 electoral campaign. The information was published by the newspaper O Estado de S. Paulo. Juscelino informed the Superior Electoral Court that he made 23 trips through the company Rotorfly Taxi Aéreo from August to September 2022 during the campaign. In the accounting of expenses, it is stated that three alleged campaign workers carried out the trips. In addition, Juscelino is suspected of having favored the contractor Engefort in a public works project of the Codevasf.
== History == CART was found by examining changes in the brain following cocaine or amphetamine administration. CART mRNA increased with cocaine administration. One of the goals was to find an endogenous anoretic substance. CART inhibited rat food intake by as much as 30 percent. When naturally occurring CART peptides were blocked by means of injecting antibodies for CART, feeding was increased. This led to suggestions that CART may play a role – though not being the only peptide – in satiety. In the late 1980s, researchers started to synthesize structurally cocaine-like and functionally CART-like substances in order to find medications that could help treat eating disorders as well as cocaine abuse. Chemically, these substances belong to phenyltropanes.
Sources: en.wikipedia.org
==== United States ==== Neither Amanita muscaria nor muscimol is considered a controlled substance by the Federal government of the United States. The United States Food and Drug Administration (FDA) has deemed Amanita muscaria and its constituents, including muscimol, unapproved for conventional foods and is also evaluating their use in dietary supplements. Agriculture regulators in Florida actioned against one seller of Amanita products after the agency had determined such products were considered adulterated under state law. Muscimol may be regulated on a state level. Louisiana State Act 159 banned the possession and cultivation of the Amanita muscaria except for ornamental or aesthetic purposes. Except as a constituent of lawfully manufactured food or dietary supplements, the act outlaws preparations of the Amanita muscaria intended for human consumption, including muscimol.
=== 16 April === Ukraine and Russia conducted an Orthodox Easter prisoner swap. Some one hundred and thirty Ukrainian POWs were returned to Ukraine in exchange for an unknown number of Russian soldiers. Ukrainian officials said that the remains of some eighty-two deceased Ukrainian soldiers were retrieved from territory controlled by Russia. Chinese defense minister Li Shangfu met with Putin amid reports of Ukrainian forces finding an increasing number of Chinese components in Russian weapons, and leaked classified documents from the United States about China's alleged plans to covertly supply Russia with weapons.
=== Natural degradation or clearance === Unfractionated heparin has a half-life of about one to two hours after infusion, whereas low-molecular-weight heparin's half-life is about four times longer. Lower doses of heparin have a much shorter half-life than larger ones. Heparin binding to macrophage cells is internalized and depolymerized by the macrophages. It also rapidly binds to endothelial cells, which precludes the binding to antithrombin that results in anticoagulant action. For higher doses of heparin, endothelial cell binding will be saturated, such that clearance of heparin from the bloodstream by the kidneys will be a slower process.
== Erinacine C == Erinacine C has also been observed to activate the transcription factor Nrf2 and has been observed to play a role in neurogenesis and neuroplasticity. Stimulator of NGF synthesis in vitro((299.1 ± 59.6) pg/mL at 1.0 mmol/L)
MDO-NPA (10,11-methylenedioxy-N-n-propylnoraporphine) is a synthetic aporphine derivative used as a research tool in neuropharmacology. It was developed as a methylenedioxy prodrug of N-n-propylnorapomorphine (NPA). A noteworthy advantage that the MDO-NPA congener has over NPA and apomorphine is that MDO-NPA has a high oral bioavailability, whereas the other two do not and must be delivered via subcutaneous injection or intraperitoneally.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.